Latest News

W. R. Berkley Corporation ( NYSE:WRB ) is about to trade ex-dividend in the next three days. The ex-dividend date is...

As the Canadian market navigates through a landscape marked by elevated oil prices and inflation, alongside resilient retail sales and sector rotation, investors are keenly observing opportunities that align with these economic conditions. Penny stocks, though an outdated term, continue to represent intriguing investment possibilities within this context. Typically associated with smaller or newer companies, these stocks offer potential growth at lower price points and can be particularly...

Par Pacific Holdings (PARR) has drawn investor attention after recent share price moves, with the stock closing at $50.89. The mixed return pattern across the past week, month, and past 3 months is prompting closer scrutiny. See our latest analysis for Par Pacific Holdings. Over the past year, Par Pacific Holdings has combined a strong 1-year total shareholder return of 85.8% with a 42.07% year to date share price gain. However, shorter term share price momentum has faded, with the 30 day...

BJ's Wholesale Club Holdings (BJ) stock has been under pressure recently, with the share price down about 13% over the past month and about 12% over the past 3 months, prompting closer attention from investors. See our latest analysis for BJ's Wholesale Club Holdings. Zooming out, BJ's Wholesale Club Holdings has seen its share price weaken recently, with the latest close at $85.22 and short term share price pressure contrasting with stronger multi year total shareholder returns. If this...

GE Vernova (GEV) is back in focus after Bernstein SocGen kicked off coverage with an Outperform rating, citing record backlogs, strong guidance, and heavy demand related to decarbonization and AI-driven data centers. See our latest analysis for GE Vernova. The recent analyst coverage has arrived on top of strong momentum, with GE Vernova’s share price returning 63.3% year to date and 30.4% over 90 days, while its 1 year total shareholder return of 127.0% reflects how investors have been...

Avery Dennison recently reported past first-quarter fiscal 2026 results that exceeded Wall Street expectations on both revenue and adjusted earnings per share, despite earlier operational challenges. This contrast between stronger-than-expected fundamentals and earlier business softness raises questions about how quickly the company’s execution can realign with analyst optimism. Next, we’ll explore how this stronger-than-expected quarter, alongside continued analyst optimism, reshapes Avery...

Groupe Dynamite (TSX:GRGD) is back in focus after first quarter results and guidance changes triggered sharp share price swings, fresh analyst views, and renewed debate about the company’s growth profile and valuation. See our latest analysis for Groupe Dynamite. The sharp first quarter reaction comes after a volatile spell for Groupe Dynamite, with a 7 day share price return down 26.26% and a 30 day share price return down 32.18%. At the same time, a very large 1 year total shareholder...

Sarepta Therapeutics recently reported mixed progress across its rare disease portfolio, with Duchenne muscular dystrophy gene therapy Elevidys showing signs of near-term stabilization while its emerging siRNA programs gained increased attention from analysts and partners. These developments underscore how Sarepta’s future now hinges on regulatory decisions around Elevidys and the maturation of its siRNA pipeline, set against a tougher safety and operational backdrop. We’ll now explore how a...

Recent news highlights Halozyme Therapeutics’ use of its proprietary ENHANZE technology and recombinant human hyaluronidase enzyme to broaden subcutaneous delivery of biologic drugs through partnerships with major pharmaceutical companies including F. Hoffmann-La Roche, Pfizer, Bristol Myers Squibb, and others. An interesting aspect is how these collaborations, alongside strong revenue, earnings growth, and high free cash flow margins, are reinforcing Halozyme’s position as an enabling...

The US Section 301 investigation into Germany’s pharmaceutical pricing has put the spotlight on how global trade policy can affect large US-based drug companies. Tariffs or tighter trade terms could reshape revenue streams, research budgets and investor sentiment across the sector. For investors, this news is less about short term noise and more about understanding which businesses look relatively well positioned if tensions persist or ease. This article breaks down how the probe could matter...

In the past week, Arqit Quantum agreed to pay US$7 million to settle a lawsuit alleging misrepresentations about its quantum encryption technology and revenue sources, closing a four-year legal dispute. The resolution removes a legal overhang that had clouded perceptions of Arqit’s core technology and business model, potentially clarifying how customers and partners assess its role in post‑quantum cybersecurity. With the lawsuit settled and key questions about prior disclosures addressed,...

Earlier this week, Scorpio Tankers Inc. released an operational update detailing its second-quarter 2026 Time Charter Equivalent rates alongside recent vessel sales and a fleet expansion pipeline with newbuildings scheduled through 2030. This disclosure gives investors a clearer view of how current chartering conditions and long-term fleet planning could influence the company’s earnings capacity and capital allocation decisions. We’ll now examine how the updated Time Charter Equivalent rates...

Bank of America’s decision to initiate coverage on TeraWulf (WULF), highlighting its shift toward high performance computing and AI infrastructure projects such as Lake Mariner and the Muskie Data Campus, has put the stock firmly on investors’ radar. See our latest analysis for TeraWulf. Recent interest in TeraWulf has coincided with sharp price momentum, including a 4.02% 1 day share price return, 33.98% 30 day share price return and a 91.92% 90 day share price return. Over 1 year the total...

Patterson-UTI Energy (PTEN) has drawn fresh attention after recent share price weakness, with the stock down about 18% over the past month and nearly 8% over the past 3 months. See our latest analysis for Patterson-UTI Energy. At a share price of $10.04, Patterson-UTI Energy has seen momentum cool in the short term, with a 7 day share price return of down 12.62% and a 30 day share price return of down 18.24%. This comes despite a year to date share price return of 55.18% and a 1 year total...

With central banks talking tougher on inflation and bond yields reacting to every move in oil and policy expectations, many investors are looking for stocks backed by solid balance sheets rather than hype. The Solid Balance Sheet and Fundamentals screener focuses on companies with high return on equity, a track record of sound past performance and conservative finances. In a world where growth signals are mixed and inflation patterns vary by region, that kind of quality filter can help you...

Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after announcing a broad slate of clinical and real-world data presentations at the 2026 Congress of the European Hematology Association in Stockholm. See our latest analysis for Swedish Orphan Biovitrum. The latest EHA2026 data slate comes after a period of strong share price momentum for Swedish Orphan Biovitrum, with a 90 day share price return of 22.48% and a 1 year total shareholder return of 61.48%, suggesting investors are...

Madison Square Garden Entertainment recently faced a major data breach, with hackers releasing 42 gigabytes of visitor information, including biometric and facial-recognition data tied to an alleged exposure of more than 26 million records, prompting multiple proposed class action lawsuits over its data protection practices. The incident has intensified scrutiny of MSG Entertainment’s controversial use of facial recognition technology and raised questions about how it safeguards sensitive...

The United States market has experienced a positive trend, climbing 1.7% in the last week and showing a substantial 25% increase over the past year, with earnings projected to grow by 19% annually in the coming years. In such an environment, identifying stocks that are priced below their estimated value can be crucial for investors looking to capitalize on potential growth opportunities, as these stocks may offer significant upside potential relative to their current market price.

Over the last 7 days, the United States market has risen 1.7% and climbed 25% in the past year, with earnings expected to grow by 19% per annum in the coming years. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often align management interests with shareholder value while capitalizing on expanding revenues.

Over the last 7 days, the United States market has risen 1.7%, and over the past year, it has climbed 25%, with earnings forecasted to grow by 19% annually. In light of these favorable market conditions, identifying stocks with strong financials becomes crucial for investors seeking value and growth potential. Penny stocks—often smaller or newer companies—may seem like a throwback term, but they continue to offer intriguing opportunities when backed by solid fundamentals, making them worthy...

Securitas AB recently outlined its 2030 strategy, setting new financial targets including a long-term ambition for an operating margin above 10% and average annual earnings per share growth of 10% over a business cycle. The plan marks a clear shift toward technology- and intelligence-led security services, signaling a stronger emphasis on data, analytics and innovation-driven solutions. Next, we’ll examine how Securitas’ 2030 technology-focused roadmap and earnings per share target reshape...

In recent months, STERIS has reported slowing revenue growth and flat adjusted operating margins, even as it continues investing in new sterility-assurance manufacturing capacity and executing a large share repurchase program. This combination of modest operating progress and sizable capital deployment has prompted investors to revisit how resilient STERIS’s infection-prevention, service, and consumables platform really is across its Healthcare, Applied Sterilization Technologies, and Life...

Nutex Health recently reported industry-leading operating efficiency, year-over-year revenue growth and a sharp improvement in net profit, alongside a rise in its institutional shareholding to 46.78% and a low beta profile indicating relatively muted share price swings versus the broader market. The company now ranks first in financial health and operating efficiency and has seen a very large quarter-on-quarter increase in institutional ownership, while technical indicators suggest strong...

Black Stone Minerals (BSM) is back on investors’ radar after recent trading left the unit price around $14.01, with returns mixed over the past month, the past 3 months, and the past year. See our latest analysis for Black Stone Minerals. Over the past year, Black Stone Minerals has combined a modest year to date share price gain of 3.7% with a stronger 1 year total shareholder return of 16.12%, while its 5 year total shareholder return of 122.82% points to momentum that has built over a...